- 04 June | MGP Strategy Series | GS Paper 4 (Ethics) with AIR 7 A.R. Rajah Mohaideen Click Here to register for the session →
- 04 June | GS Advance Program begins from 4th June 2026 | First 2 classes open to all Click Here to register for the event →
- 05 June | MGP Strategy Series | GS Paper 3 Strategy Session with AIR 406 Mannat Luthra Click Here to register for the session
- 06 June | Open Orientation on Essay Guidance Program (EGP 2026) Click Here to register →
- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
- 07 June | Sociology Optional Strategy Session with AIR 10 Ujjwal Priyank Click Here to register →
Contents
Source: The post is based on the article “What is the new US FDA-approved treatment for early Alzheimer’s?” published in Indian Express on 10th January 2023
What is the News?
The US Food and Drug Administration(FDA) has approved a new Alzheimer’s drug named Lecanemab which is to be marketed as Leqembi.
What is Alzheimer disease?
What is Lecanemab?
Lecanemab, sold under the brand name Leqembi, is a medication approved for the treatment of Alzheimer’s disease.
Working of the drug: The drug is a monoclonal antibody that binds itself to a protein in the brain called Amyloid beta.
– By doing so, it helps the body destroy these proteins. People with Alzheimer’s have high levels of Amyloid beta in their brains and, in the trial, Leqembi significantly lowered those amounts.
– However, it remains unclear whether the protein causes Alzheimer’s or how reducing it affects the disease’s progression.
Who can use this drug?
The drug should be used only for patients in the early and mild stages of Alzheimer’s disease, matching the status of patients in the clinical trials of the drug.
– It instructs doctors not to treat patients without doing tests to confirm that they have one of the hallmarks of Alzheimer’s: a buildup of the protein amyloid, which Leqembi (like Aduhelm) attacks.
